Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Stivarga
Regorafenib is an oral multi-kinase inhibitor that targets multiple protein kinases involved in tumor angiogenesis, oncogenesis, and the tumor microenvironment. It is used to treat certain types of colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC). Regorafenib works by blocking these kinases, which helps to slow or stop the growth and spread of cancer cells.
For the treatment of certain types of colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC) that have progressed or spread after prior therapies.
Severe and fatal hepatotoxicity, including liver failure, has been reported. Severe and fatal hemorrhage has been reported. Severe and sometimes fatal skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have occurred. Impaired wound healing complications have been reported. Embryo-fetal toxicity. Hypertension and reversible posterior leukoencephalopathy syndrome have also been observed.
Outcome:
Increased risk of bleeding
Mechanism:
Regorafenib can inhibit CYP2C9, increasing warfarin levels.
Outcome:
Reduced regorafenib absorption
Mechanism:
Antacids can alter gastric pH, affecting regorafenib absorption.
Outcome:
Minimal interaction expected
Mechanism:
No significant interaction anticipated.
Most likely new formulation: Controlled-release formulation for improved patient compliance (2025, 80% confidence)
Based on current usage trends and ongoing clinical trials, there is a 70% likelihood of regorafenib being approved for additional cancer indications within the next 5 years.
Multi-Kinase Inhibitor, Antineoplastic Agent
Diarylurea